Selective COX-2 inhibitors as chemopreventive and therapeutic agents

Drugs of Today

Volumn 39, Issue 3, 2003, Pages 203-211

  Barton Grossman, H ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Box 446 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EFLORNITHINE; FLUOROURACIL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; TRASTUZUMAB;

ACTINIC KERATOSIS; ADENOMATOUS POLYP; ADENOMATOUS POLYPOSIS GENE; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLON POLYP; COLORECTAL CANCER; ESOPHAGUS CANCER; GENE; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; REVIEW; SKIN CANCER; UTERINE CERVIX CANCER;

ANIMALS; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0037368097     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.3.799454     Document Type: Review

References (74)

1. Gee, J., Sabichi, A., Grossman, H.B. Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol 2002, 43: 277-86.
2. Thun, M.J., Henley, S.J., Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94: 252-66.
3. Liu, C.H., Chang, S.H., Narko, K. et al. Over-expression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276: 18563-9.
4. Bol, D.K., Rowley, R.B., Ho, C.P. et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 2002, 62: 2516-21.
5. Fischer, S.M., Lo, H.H., Gordon, G.B. et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999, 25: 231-40.
6. Pentland, A.P., Schoggins, J.W., Scott, G.A., Khan, K.N., Han, R. Reduction of UV-induced skin tumors in hairless mice by selective COX2 inhibition. Carcinogenesis 1999, 20: 1939-44.
7. Williams, C.S., Watson, A.J., Sheng, H., Helou, R., Shao, J., DuBois, R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 2000, 60: 6045-51.
8. Oshima, M., Murai, N., Kargman, S. et al. Chemoprevention of intestinal polyposis in the Apc-delta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001, 61: 1733-40.
9. Nakatsugi, S., Fukutake, M., Takahashi, M. et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res 1997, 88: 1117-20.
10. Jacoby, R.F., Seibert, K., Cole, C.E., Kelloff, G., Lubet, R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000, 60: 5040-4.
11. Fukutake, M., Nakatsugi, S., Isoi, T. et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998, 19: 1939-42.
12. Sawaoka, H., Kawano, S., Tsuji, S., Tsujii, M., Murata, H., Hori, M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: Possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 1998, 27 (Suppl. 1): S47-52.
13. Grubbs, C.J., Lubet, R.A., Koki, A.T. et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000, 60: 5599-602.
14. Liu, X.H., Kirschenbaum, A., Yao, S., Lee, R., Holland, J.F., Levine, A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000, 164: 820-5.
15. Petersen, C., Petersen, S., Milas, L., Lang, F.F., Tofilon, P.J. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000, 6: 2513-20.
16. Kishi, K., Petersen, S., Petersen, C. et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000, 60: 1326-1331.
17. Kundu, N., Fulton, A.M. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002, 62: 2343-6.
18. Grosch, S., Tegeder, I., Niederberger, E., Brautigam, L., Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15: 2742-4.
19. Masferrer, J.L., Leahy, K.M., Koki, A.T. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60: 1306-11.
20. Masferrer, J.L., Koki, A., Seibert, K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci 1999, 889: 84-6.
21. Williams, C.S., Tsujii, M., Reese, J., Dey, S.K., DuBois, R.N. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000, 105: 1589-94.
22. Nishimura, G., Yanoma, S., Mizuno, H., Kawakami, K., Tsukuda, M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999, 90: 1152-62.
23. Munkarah, A.R., Morris, R., Baumann, P. et al. Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig 2002, 9: 168-73.
24. Waskewich, C., Blumenthal, R.D., Li, H.L.,-Stein, R., Goldenberg, D.M., Burton, J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002, 62: 2029-33.
25. 2+-ATPases. A plausible link with its antitumor effect and cardiovascular risks. Biochem J 2002, 366: 831-7.
26. Meyer-Siegler, K. COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells. Molecular Medicine 2001, 7: 850-60.
27. Elder, D.J., Halton, D.E., Playle, L.C., Paraskeva, C. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002, 99: 323-7.
28. Arico, S., Pattingre, S., Bauvy, C. et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002, 277: 27613-21.
29. Song, X.Q., Lin, H.P., Johnson, A.J. et al. Cyclo-0 oxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002, 94: 585-91.
30. Masferrer, J. Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 2001, 7: S144-50.
31. Half, E., Tang, X.M., Gwyn, K., Sahin, A., Wathen, K., Sinicrope, F.A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002, 62: 1676-81.
32. Ristimaki, A., Sivula, A., Lundin, J. et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62: 632-5.
33. Costa, C., Soares, R., Reis-Filho, J.S., Leitao, D., Amendoeira, I., Schmitt, F.C. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002, 55: 429-34.
34. Matsumoto, Y., Ishiko, O., Deguchi, M., Nakagawa, E., Ogita, S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001, 8: 31-6.
35. Denkert, C., Kobel, M., Pest, S. et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002, 160: 893-903.
36. Ferrandina, G., Ranelletti, F.O., Lauriola, L. et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 2002, 85: 305-310.
37. Ferrandina, G., Lauriola, L., Distefano, M.G. et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002, 20: 973-81.
38. Gaffney, D.K., Holden, J., Davis, M., Zempolich, K., Murphy, K.J., Dodson, M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001, 49: 1213-7.
39. Fujiwaki, R., Iida, K., Kanasaki, H., Ozaki, T., Hata, K., Miyazaki, K. Cyclooxygenase-2 expression in endometrial cancer: Correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002, 33: 213-9.
40. Hasturk, S., Kemp, B., Kalapurakal, S.K., Kurie, J.M., Hong, W.K., Lee, J.S. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002, 94: 1023-31.
41. Hida, T., Yatabe, Y., Achiwa, H. et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58: 3761-4.
42. Wolff, H., Saukkonen, K., Anttila, S., Karjalainen, A., Vainio, H., Ristimaki, A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58: 4997-5001.
43. Brabender, J., Park, J., Metzger, R. et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002, 235: 440-3.
44. Achiwa, H., Yatabe, Y., Hida, T. et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999, 5: 1001-5.
45. Khuri, F.R., Wu, H., Lee, J.J. et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001, 7: 861-7.
46. El-Sheikh, S.S., Madaan, S., Alhasso, A., Abel, P., Stamp, G., Lalani, E.N. Cyclooxygenase-2: A possible target in schistosoma-associated bladder cancer. BJU Int 2001, 88: 921-7.
47. Komhoff, M., Guan, Y.F., Shappell, H.W. et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000, 157: 29-35.
48. Shirahama, T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000, 6: 2424-30.
49. Mohammed, S.I., Knapp, D.W., Bostwick, D.G. et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999, 59: 5647-50.
50. Bostrom, P.J., Aaltonen, V., Soderstrom, K.O., Uotila, P., Laato, M. Expression of cyclooxygenase-1 and -2 in urinary bladder carcinoma in vivo and in vitro and prostaglandin E-2 synthesis in cultured bladder cancer cells. Pathology 2001, 33: 469-74.
51. Shirahama, T., Arima, J., Akiba, S., Sakakura, C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92: 188-93.
52. Zha, S., Gage, W.R., Sauvageot, J. et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001, 61: 8617-23.
53. Lee, L.M., Pan, C.C., Cheng, C.J., Chi, C.W., Liu, T.Y. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001, 21: 1291-4.
54. Niijima, M., Yamaguchi, T., Ishihara, T. et al. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 2002, 94: 1565-73.
55. Koga, H., Sakisaka, S., Ohishi, M. et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology 1999, 29: 688-96.
56. Karim, M.M., Hayashi, Y., Inoue, M., Imai, Y., Ito, H., Yamamoto, M. Cox-2 expression in retinoblastoma. Am J Ophthalmol 2000, 129: 398-401.
57. Gallo, O., Franchi, A., Magnelli, L. et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001, 3: 53-61.
58. Shono, T., Tofilon, P.J., Bruner, J.M., Owolabi, O., Lang, F.F. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 2001, 61: 4375-81.
59. Edwards, J.G., Faux, S.P., Plummer, S.M. et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002, 8: 1857-62.
60. Kandil, H.M., Tanner, G., Smalley, W., Halter, S., Radhika, A., Dubois, R.N. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001, 46: 785-9.
61. Morris, C.D., Armstrong, G.R., Bigley, G., Green, H., Attwood, S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001, 96: 990-6.
62. Kawabe, A., Shimada, Y., Uchida, S. et al. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 2002, 62: 46-54.
63. Buskens, C.J., Van Rees, B.P., Sivula, A. et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002, 122: 1800-7.
64. Uefuji, K., Ichikura, T., Mochizuki, H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001, 76: 26-30.
65. Ratnasinghe, D., Tangrea, J.A., Roth, M.J., et al. Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus. Oncology Reports 1999, 6: 965-8.
66. Rajnakova, A., Moochhala, S., Goh, P.M., Ngoi, S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001, 172: 177-85.
67. Ohno, R., Yoshinaga, K., Fujita, T. et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001, 91: 1876-81.
68. Khan, K.N.M., Masferrer, J.L., Woerner, B.M., Soslow, R., Koki, A.T. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 2001, 36: 865-9.
69. Sinicrope, F.A., Lemoine, M., Xi, L. et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999, 117: 350-8.
70. Dimberg, J., Samuelsson, A., Hugander, A., Soderkvist, P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999, 45: 730-2.
71. Sheehan, K.M., Sheahan, K., O'Donoghue, D.P. et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999, 282: 1254-7.
72. Cianchi, F., Cortesini, C., Bechi, P. et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001, 121: 1339-47.
73. Tani, K., Nakazaki, Y., Hase, H. et al. Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells. Cancer Chemother Pharmacol 2000, 46: S73-6.
74. Phillips, R.K., Wallace, M.H., Lynch, P.M. et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50: 857-60.